Anixa Biosciences (ANIX) Competitors $3.33 -0.03 (-0.92%) As of 09:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. TRML, SVRA, ERAS, TECX, ETON, ITOS, VIGL, RVNC, SLDB, and FULCShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Tourmaline Bio (TRML), Savara (SVRA), Erasca (ERAS), Tectonic Therapeutic (TECX), Eton Pharmaceuticals (ETON), iTeos Therapeutics (ITOS), Vigil Neuroscience (VIGL), Revance Therapeutics (RVNC), Solid Biosciences (SLDB), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Its Competitors Tourmaline Bio Savara Erasca Tectonic Therapeutic Eton Pharmaceuticals iTeos Therapeutics Vigil Neuroscience Revance Therapeutics Solid Biosciences Fulcrum Therapeutics Tourmaline Bio (NASDAQ:TRML) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Do analysts rate TRML or ANIX? Tourmaline Bio presently has a consensus price target of $49.33, indicating a potential upside of 162.06%. Anixa Biosciences has a consensus price target of $9.00, indicating a potential upside of 170.35%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media favor TRML or ANIX? In the previous week, Anixa Biosciences had 10 more articles in the media than Tourmaline Bio. MarketBeat recorded 12 mentions for Anixa Biosciences and 2 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.52 beat Anixa Biosciences' score of 0.51 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Anixa Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in TRML or ANIX? 91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 13.0% of Tourmaline Bio shares are held by company insiders. Comparatively, 25.3% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, TRML or ANIX? Anixa Biosciences has higher revenue and earnings than Tourmaline Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$73.21M-$3.21-5.86Anixa Biosciences$210K510.61-$12.55M-$0.38-8.76 Is TRML or ANIX more profitable? Tourmaline Bio's return on equity of -26.75% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -26.75% -26.11% Anixa Biosciences N/A -68.17%-60.38% Which has more risk & volatility, TRML or ANIX? Tourmaline Bio has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. SummaryAnixa Biosciences beats Tourmaline Bio on 8 of the 15 factors compared between the two stocks. Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.80M$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-9.0520.3628.1819.72Price / Sales510.61290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book5.647.768.235.67Net Income-$12.55M-$55.11M$3.23B$257.51M7 Day Performance6.02%0.19%-0.61%-0.16%1 Month Performance-9.54%10.80%6.63%9.89%1 Year Performance5.68%-0.68%27.07%15.08% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences2.9455 of 5 stars$3.33-0.9%$9.00+170.4%+4.3%$110.80M$210K-9.055Gap UpTRMLTourmaline Bio1.9922 of 5 stars$15.96-2.8%$49.33+209.1%+16.0%$409.85MN/A-4.9744News CoveragePositive NewsSVRASavara2.1633 of 5 stars$2.34+6.8%$5.60+139.3%-53.4%$404.45MN/A-4.8720High Trading VolumeERASErasca2.9433 of 5 stars$1.42-1.4%$4.57+221.9%-55.4%$402.27MN/A-2.29120TECXTectonic Therapeutic2.9843 of 5 stars$20.78-2.6%$83.60+302.3%+31.3%$388.03MN/A-2.84120Positive NewsETONEton Pharmaceuticals1.956 of 5 stars$14.39-0.4%$29.67+106.2%+286.9%$385.94M$39.01M-79.9420ITOSiTeos Therapeutics3.3136 of 5 stars$10.07-1.1%$15.86+57.5%-41.5%$385.38M$35M-3.3190VIGLVigil Neuroscience3.815 of 5 stars$7.99flat$10.80+35.2%+87.7%$381.04MN/A-3.9040RVNCRevance Therapeutics2.61 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500SLDBSolid Biosciences3.2742 of 5 stars$4.91-2.4%$15.10+207.5%-42.1%$380.57M$8.09M-1.64100News CoverageAnalyst RevisionFULCFulcrum Therapeutics0.5946 of 5 stars$7.02+1.4%$6.29-10.5%-9.0%$378.94M$80M-100.27100 Related Companies and Tools Related Companies Tourmaline Bio Alternatives Savara Alternatives Erasca Alternatives Tectonic Therapeutic Alternatives Eton Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Vigil Neuroscience Alternatives Revance Therapeutics Alternatives Solid Biosciences Alternatives Fulcrum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
